Profile of T Cell Recognition of HIV Type 1 Consensus Group M Gag and Nef Peptides in a Clade A1- and D-Infected Ugandan Population

Jennifer Serwanga,¹ Susan Mugaba,¹ Edward Pimego,¹ Bridget Nanteza,¹ Fred Lyagoba,¹ Susan Nakubulwa,¹ Laura Heath,² Rebecca N. Nsubuga,¹ Nicaise Ndembu,¹ Frances Gotch,³ and Pontiano Kaleebu^{1,4}

Abstract

Reagents for evaluating non-clade B HIV-specific T cell responses are uncommon. Peptides based on highly conserved HIV-1 consensus group M sequences that are phylogenetically closer to most circulating strains may provide potential alternative reagents in populations with diverse infections, and may be relevant for vaccine design. Recognition of such reagents in clade A1- and D-infected populations has not been previously evaluated. Interferon (IFN)- γ ELISpot assay was used to evaluate T cell recognition of Gag and Nef peptides based on consensus group M sequences in 50 treatment-naïve adults predominantly infected with HIV-1 clades A1 and D. Gag-induced T cell responses were correlated with *gag* sequence diversity. Infecting clades were determined from *gag* sequences for 45 of the 50 subjects as 40% clade A1 (18/45), 45% clade D (20/45), 2% clade C (1/45), 2% A1/C recombinant (1/45), 2% A1/D (1/45), 7% CRF10_CD (3/45), and 2% U (unclassifiable) (1/45). The mean genetic divergence and diversity of clade A and D *gag* region compared to group M consensus sequences at synonymous and nonsynonymous nucleotide and amino acid levels were not always significant. Gag peptides were targeted at significantly higher frequency [88% (44/50)] than Nef [64% (32/50)]; $p=0.014$, although their mean IFN- γ magnitudes were comparable ([3703 (95% CI 2567–4839)] vs. [2120 (95% CI 478–3762)]), respectively. Measurable virus-induced IFN- γ responses were detected in 96% (48/50) individuals, primarily targeting the more conserved Gag p24 and Nef central core regions. Use of these reagents to screen for HIV-specific IFN- γ responses may mitigate the challenge of viral diversity; although this targeting is apparently biased toward a few highly conserved epitopes.

Introduction

GROUP M VIRUSES DOMINATE the global HIV-1 epidemic and comprise 13 circulating subtypes and subsubtypes (A1–A4, B, C, D, F1–F2, G, H, J, and K), over 49 CRFs, in addition to various URFs (<http://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html>, Feb 2011); these occur in distinct geographic locations.^{1–4} Although the bulk of HIV-1 infection and diversity occurs in sub-Saharan Africa,^{2,5} detailed virus characterizations have focused on clade B viruses, which predominate in Europe and North America, possibly due to the scarcity of non-clade B virus reagents. Potential immunogens like centralized sequences,^{6–10} polyvalent mosaic sequences,^{11–15} or highly conserved sequences¹⁶ have been pursued, and in some cases these increased the breadths and magnitudes of responses.^{11,12} Such prospective immu-

nogens may also be useful for global vaccine design and evaluation.

Most HIV-1-infected individuals have circulating T cells that target epitopes within the Gag and Nef proteins. Use of peptides based on consensus group M sequences to identify such epitopes may circumvent the scarcity of reagents required for use in non-clade B-infected populations. Here, we report findings for the T cell recognition of these reagents by 50 untreated subjects largely infected with HIV-1 clades A1 and D.

Materials and Methods

Study population

Fifty prevalent HIV-infected antiretroviral treatment (ART)-naïve consenting adults, consecutively recruited from

¹MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda.

²Department of Microbiology, University of Washington, School of Medicine, Seattle, Washington.

³Department of Immunology, Imperial College, Chelsea & Westminster Hospital, London, United Kingdom.

⁴London School of Hygiene and Tropical Medicine, London, United Kingdom.

attendees of The AIDS Support Organisation (TASO) clinic Entebbe, were evaluated at a single time point between August and September 2007. Eligibility was determined from CD4 T cell counts enumerated within 6 months prior to sample collection. All study subjects had CD4 T cell counts ≥ 350 cells/ μ l, and provided written informed consent for collection and subsequent analysis of their specimens. The study was approved by the Uganda Virus Research Institute Ethics Review Board and the Uganda National Council of Science and Technology.

Plasma viral load, CD4 T cell count, and HLA analyses

CD4⁺ T cell counts and HLA class I typing were determined as previously described.¹⁷ Plasma viral loads were determined by HIV RNA copy quantification using the Roche Amplicor MONITOR 1.5 protocol (Roche Molecular Systems, Roche, Nutley, NJ). The HIV RNA assay lower detection limit was 400 HIV-1 RNA copies/ml.

HIV peptides and preparation of pools

Peptides were 15 amino acids long, overlapping by 11 amino acids and spanning HIV-1 Gag (#11057; 129 peptides) and Nef (#11055; 53 peptides) consensus group M sequences (<https://www.aidsreagent.org/Index.cfm>). Up to 10 distinct peptides were pooled at 2 μ g/ml per peptide so that each peptide appeared twice in both a protein and a matrix pool to allow for subsequent single peptide mapping. Duplicate wells containing 100,000 peripheral blood mononuclear cells (PBMCs) per well were incubated with peptide pools at 37°C in 5% CO₂ in air for 18 h. ELISpot plates were developed using Nova-Red substrate (Vector, Burlingame, CA) according to

the manufacturer's protocols. Test wells inducing interferon (IFN)- γ responses in both pools that shared a peptide were considered positive, and were confirmed by retesting. Assay consistency was monitored using cryopreserved PBMCs of known reactivity to human cytomegalovirus, Epstein-Barr virus, and influenza virus (CEF) control peptide pools (NIH AIDS Reference Reagent Repository, #9808) at 1 μ g/ml per peptide. Positive controls were two wells containing phytohemagglutinin (PHA)-treated PBMCs. Background response was determined from four wells containing cells in media alone and two wells with media only. Spots were counted using the AID ELISpot Reader system (GMBH, Germany). Virus-induced IFN- γ -secreting T cells were enumerated as spot-forming units per million PBMCs (SFU/10⁶ PBMCs). The test acceptance criteria were ≥ 300 spots per PHA well, ≤ 100 spots in all six background wells, and ≤ 5 spots in the two wells containing media only. Test wells with net response ≥ 100 SFU/10⁶ PBMCs were considered positive. All ELISpot data are presented as net SFU/10⁶ PBMCs after subtracting three times the mean of the background wells. The magnitude of IFN- γ was defined as the total SFU/10⁶ PBMCs from all responding peptides constituting the evaluated protein. Breadth was defined as the total number of peptides recognized.

DNA extraction and polymerase chain reaction amplification

Viral DNA was extracted from 200 μ l of whole blood using the QIAmp DNA Mini Kit protocol (Qiagen Inc, Chatsworth, CA). Gag-specific primers were used in a nested PCR to amplify a 1.7-kb pair *gag* gene encompassing the p17, p24, and

FIG. 1. Distribution of host HLA alleles in the study population. The frequency and distribution of HLA A (A), HLA B (B), and HLA C (C) alleles presenting interferon (IFN)- γ responses in this population is illustrated. HLA B alleles are further classified according to known HLA supertypes B07, B27, B44, and B58.

p15 regions, as described elsewhere.¹⁸ The amplified products were purified with a QIAquick PCR purification kit (Qiagen, Valencia, CA) and sequenced in house using a Beckman CEQ 8000 automated capillary DNA sequencer. The sequence data were assembled and manually edited using Sequencher 4.7 software (Gene Codes Corporation, Ann Arbor, MI).

Phylogenetic analysis and assignment of infecting clades

Viroblast¹⁹ was used to blast nucleotide sequences against the HIV-1 database. Clade classification and recombinant patterns were determined using the REGA subtyping tool²⁰ and further confirmed using phylogenetic analysis. Maximum likelihood phylogenetic reconstruction was performed using PhyML based on the General Time-Reversible model with gamma distributed rate variation among sites. Bootstrap support values were obtained using 500 replicates. The similarity plots were obtained using SimPlot (v3.5.1: S. Ray, Johns Hopkins University, Baltimore, MD) as previously described,²¹ with a window of 500 nt and steps of 50 nt. Subtype reference sequences at the Los Alamos Database were used to automatically align the generated sequences using MUSCLE

v3.7²² and were manually refined in MacClade v4.08 software (Sinauer Associates, Inc., Sunderland, MA).

Statistical analysis

Medians with interquartile ranges (IQR), proportions, and correlations were compared using the Mann-Whitney rank, Fisher's exact, and Spearman's rank correlation coefficient tests, respectively. Magnitudes and breadths of Gag (129 peptides) or Nef (53 peptides) recognition were evaluated as means in order to adjust for differences in the number of peptides constituting the protein. Genetic divergence from consensus amino acid sequences was compared using Wilcoxon rank sums tests. Graph Pad 5.0 was used for all the graphical presentations of the data. All analyses were performed using Stata V 10.0 (Stata Corp, TX).

Results

Cohort characteristics and infecting HIV gag clades

Fourteen males (28%) and 36 females (72%) with median (IQR) enrollment age 37 (31–41) years, CD4 counts 538 (484–647) cells/ μ L, and plasma viral loads of 15,550 (3450–52,400)

FIG. 2. Consensus group M Gag-induced IFN- γ responses. The profile of consensus group M Gag-induced T cell recognition is shown ($n=50$) illustrating cumulative IFN- γ magnitudes (SFU/10⁶ PBMCs) to individual Gag peptides, sequences of the dominantly targeted peptides, and the circulating subject HLA alleles (A). Recognition of consensus group M Gag peptides clusters into eight regions: Gag_{17–47} (p17-I), Gag_{74–95} (p17-II), Gag_{140–194} (p24-I), Gag_{196–218} (p24-II), Gag_{245–283} (p24-III), Gag_{290–381} (p24-IV), Gag_{290–381} (p24-V), and Gag_{429–447} (p15-I) and the proportion of individuals targeting peptides within the Gag clusters are illustrated (B).

RNA copies/ml were evaluated. Subject CD4 counts for clade A1 [551; IQR 510–1046 cells/ μ l] and D infection [640; IQR 566–816 cells/ μ l] were comparable. The WHO clinical stages of HIV infection were 24% (12/50), 64% (32/50), and 12% (6/50) stage I, II, and III, respectively. The study population comprised a broad range of host HLA alleles including 16 HLA-A, 21 HLA-B, and 14 HLA-C alleles (Fig. 1A, B, and C), respectively.

Five *gag* specimens failed to amplify; thus, infecting clades were deduced for 45 of the 50 subjects as 40% clade A1 (18/45), 45% clade D (20/45), 2% clade C (1/45), 2% A1/C recombinant (1/45), 2% A1/D recombinant (1/45), 7% CRF10_CD (3/45), and 2% U (unclassifiable). The HIV-1 *gag* gene DNA sequences from this study were submitted to GenBank under accession numbers HQ702686–HQ702731. Clades A1 and D *gag* sequence mean divergence and diversity were not significantly different from that of consensus group M sequences at synonymous, nonsynonymous, and amino acid levels. Overall, genetic variation within clade A1 against consensus group M sequences was 8.4% while variation within clade D was 10% (Supplementary Table S1; Supplementary Data are available online at www.liebertonline.com/aid). These data implied that the clade A1 sequences were phylogenetically closer to the consensus group M *gag* sequences compared to clade D.

Consensus group M Gag-induced IFN- γ responses

The frequency, magnitudes, and breadths of IFN- γ responses induced by the 129 Gag peptides traversing p17 (34

peptides), p24 (60 peptides), and p15 (35 peptides) sequences were evaluated. HIV-specific IFN- γ responses were detected in all the diverse infecting clades. Gag was targeted by 90% subjects (45/50) at median magnitude 2420 (IQR 580–6445 SFU/ 10^6 PBMCs) and breadth of three peptides (IQR 2–5). Measurable IFN- γ responses were detected in 39% (50/129) of the Gag peptides comprising 35.3% (12/34) p17, 62% (31/60) p24, and 20% (7/35) p15 peptides.

The highest cumulative magnitudes were induced by five peptides: one p17 peptide, Gag_{17–31} EKIRLRPGGKKKYRL (6,435 SFU/ 10^6 PBMCs), and four p24 peptides, Gag_{160–174} EEKAFSPEVIPMFSA (18,220 SFU/ 10^6 PBMCs), Gag_{180–194} TPQDLNTMLNTVGGH (31,675 SFU/ 10^6 PBMCs), Gag_{200–214} MLKDTINEEAAEWDR (7880 SFU/ 10^6 PBMCs), and Gag_{294–304} RDYVDRFFKTLRAEQ (10,205 SFU/ 10^6 PBMCs). Thirty-five subjects targeted at least one of the five peptides; these comprised 18 clade A1, 13 clade D, one clade C, and two CRF10_CD-infected subjects. All five peptides were recognized by clade A and D infection; clade C targeted only peptide Gag_{180–194} TPQDLNTMLNTVGGH, CRF10_CD infection targeted EKIRLRPGGKKKYRL and TPQDLNTMLNTVGGH peptides, while A1/C infection did not target any of the five peptides (Fig. 2A). These data implied that targeting of the consensus group sequences depended on how well these sequences match the circulating strain.

Gag-induced responses clustered in eight regions: Gag_{17–47} (p17-I), Gag_{74–95} (p17-II), Gag_{140–194} (p24-I), Gag_{196–218} (p24-II), Gag_{245–283} (p24-III), Gag_{290–381} (p24-IV), Gag_{290–381} (p24-V), and Gag_{429–447} (p15-I) (Fig. 2B and Table 1). Targeting of

TABLE 1. RECOGNITION OF CONSENSUS GROUP M GAG CLUSTERS BY CLADE A1 AND D INFECTION

Clade A1 (n=18)								Clade D (n=20)							
p17_I (5)	p17_II (3)	p24_I (11)	p24_II (3)	p24_III (7)	p24_IV (5)	p24_V (2)	p15_I (2)	p17_I (5)	p17_II (3)	p24_I (11)	p24_II (3)	p24_III (7)	p24_IV (5)	p24_V (2)	p15_I (2)
2	2	0	0	0	0	0	0	2	0	2	0	0	0	0	0
0	1	2	1	0	0	0	0	0	0	6	2	0	0	0	0
0	1	1	0	0	3	0	0	0	0	2	0	0	0	0	0
3	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0
0	0	0	1	0	1	0	0	0	0	2	0	0	0	0	0
0	0	0	1	0	0	0	0	1	0	2	0	0	0	0	0
1	1	0	2	0	0	0	0	0	0	6	0	0	1	2	0
0	0	2	0	0	0	0	2	0	0	2	0	0	0	0	0
1	0	4	0	0	2	0	0	1	0	0	1	0	0	0	0
1	0	0	0	2	0	0	0	1	0	0	0	2	0	0	0
0	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0
0	0	2	0	2	0	0	0	0	0	2	0	0	0	0	2
0	0	0	0	0	2	2	0	0	0	2	0	0	0	2	2
0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0
0	0	2	0	0	0	0	0	0	0	0	1	0	0	0	0
0	0	0	2	0	2	0	0	2	0	1	0	0	0	0	0
1	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
0	0	0	0	0	3	0	0	3	0	0	0	0	1	0	0
1	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0
								0	0	3	0	3	0	0	0
								0	0	2	0	1	3	0	0
								0	0	0	0	1	1	0	0
								0	0	0	0	0	0	0	0

The table illustrates recognition of the eight gag clusters by clade A1- and D-infected individuals. The numbers of peptides contained in each cluster are indicated in parentheses. Each cell represents the number of peptides targeted within the respective cluster.

FIG. 3. Gag targeting and infecting HIV-1 clade. The frequency of recognition of consensus group M Gag peptides is compared in clade A ($n=20$) and D ($n=24$) infection. Gag T cell recognition clustered in eight regions: Gag_{17–47} (p17-I), Gag_{74–95} (p17-II), Gag_{140–194} (p24-I), Gag_{196–218} (p24-II), Gag_{245–283} (p24-III), Gag_{290–381} (p24-IV), Gag_{290–381} (p24-V), and Gag_{429–447} (p15-I). Overall recognition of Gag clusters (A) and recognition by clade A1- (B) and D-infected (C) individuals are illustrated.

these clusters did not significantly differ by clade except the p17-II cluster, which was exclusively targeted by clade A1-infected individuals [A1 (5/18) vs. D (0/20)]; $p=0.017$, Fisher's exact test (Fig. 3A). In line with this, data from multiple alignments of consensus M sequences against A1 and consensus M against D suggested that clade A1 was more similar to group M in the p17 region compared to clade D (Supplementary Tables S2 and S3). In line with this, we observed differential recognition of individual peptides within clusters in both clade A1- and D-infected individuals (Fig. 3B and C), reflecting differences in similarities between clade A1 and D sequences and the group M sequences. Gag p24 induced

significantly higher IFN- γ magnitudes (Fig. 4A) and breadths (Fig. 4B) compared to either p17 or p15. Responses were frequently higher when the consensus M peptide sequences matched the autologous sequences (data not shown). These data demonstrated the ability of consensus group M Gag peptides to induce high frequencies of HIV-specific IFN- γ responses in this population, principally focusing on the Gag p24 region.

Consensus group M Nef peptide IFN- γ responses and relationship with Gag responses

The frequency, magnitudes, and breadths of IFN- γ responses induced by the 53 consensus group M Nef peptides were also evaluated. Measurable Nef-specific IFN- γ responses were detected to 34% (18/53) of Nef peptides in 64% (32/50) of subjects at median magnitude 453 (0–2000 SFU/10⁶ PBMCs) and breadth of 1 peptide (IQR 0–2). The responses focused on the Nef core region and were primarily contributed by two peptides: Nef_{131–145} PGIRYPLTFGWCFKL [24% (12/50 subjects); cumulative magnitude 38,990 SFU/10⁶ PBMCs] and Nef_{104–118} KKRQEILDWVYHTQ [32% (16/50 subjects); cumulative magnitude 23,115 SFU/10⁶ PBMCs] (Fig. 5A and B).

Overall, measurable HIV-specific IFN- γ responses to Gag, Nef, or both proteins were induced in 96% of the evaluated subjects. Gag was more frequently targeted than Nef (45/50 vs. 32/50); $p=0.01$, Fisher's exact test, although the induced magnitudes and breadths did not significantly differ (Fig. 5C and D).

Discussion

HIV-1 genetic variability is a challenge to vaccine development and to the evaluation of virus-induced immune responses. Sub-Saharan Africa bears an inordinate 68% of the HIV-1 disease²³ with its circulating clades A, C, D, and the two CRFs, CRF01-AE and CRF02_AG, jointly contributing up to 75% of the global burden.⁵ Despite this, characterization of non-clade B viruses is limited partly due to the general scarcity of non-clade B reagents. HIV-1 diversity influences rates of virus transmission²⁴ and disease progression,²⁵ highlighting the importance of elucidating clade-associated properties. This possibly paved the way for evaluating HIV-1 vaccine concepts based on geographic region²⁶ and global approaches.^{10,27} Induction and subsequent detection of virus-induced immune responses are major objectives of HIV vaccine formulations. However, the resulting data may differ with type of reagent used given the high variability of HIV-1 group M viruses.^{2,28} Here, we used an IFN- γ ELISpot assay to assess recognition of peptides based on HIV-1 group M consensus sequences by HIV-1 clades A1- and D-infected subjects. We sought to determine whether use of these reagents could alleviate challenges of viral diversity and mitigate the scarcity of non-clade B reagents. We demonstrated that the evaluated group M peptide sets detected high frequencies of virus-specific IFN- γ ; both Gag and Nef were recognized although Gag peptides and were more frequently targeted. The frequency of recognition of these reagents was comparable in both clade A- and D-infected subjects in line with the fact that the mean divergence and diversity between clades were not significantly different. However, clade A- and D-infected subjects

FIG. 4. Gag-induced IFN- γ magnitudes and breadths. The magnitudes and breadths of IFN- γ responses induced by the three major Gag regions p17, p24, and p15 are illustrated. To fairly compare these magnitudes and breadths, the data are presented as means to account for differences in the number of peptides evaluated for Gag p17 ($n=34$), p24 ($n=62$), and p15 ($n=34$). Adjusted magnitudes (**A**) and adjusted breadths (**B**) of consensus group M Gag peptide-induced IFN- γ responses are compared. Floating bars represent minima and maxima while the horizontal lines represent medians.

demonstrated differential recognition of consensus group M sequences. This finding was in line with the fact that clade A1 sequences were genetically closer to the group M sequences compared to clade D, and could partly explain the observed limitation in intraclade T cell cross-reactivity among the clade D-infected individuals. These findings are in line with others that used these reagents to demonstrate superior T cell recognition of the more conserved Gag²⁹ and lesser recognition of the more variable Env³⁰ in clade B- and C-infected populations, respectively.

Recognition of the Gag and Nef peptide sets was principally attributed to targeting very few highly conserved peptides encompassing the Gag p24 and Nef core regions, respectively. This is not surprising given that both these regions are reasonably conserved.^{16,31} Accordingly, these peptide sets were not necessarily better at detecting HIV-specific T cell responses; rather, recognition depended on how well they matched the circulating virus strains. These data support the concept that while a global vaccine is the ideal goal, development of multiple locally representative HIV-1 vaccines may be more practical. Although successful vaccines were developed using conserved antigens, such strategies are challenged by extensive antigenic variability. Conventional HIV-1 vaccine attempts failed to prevent infection or to reduce postinfection viral loads,^{32,33} although hope was raised by the modest efficacy elicited by the RV144 vaccine.³⁴ Immune pressure on conserved HIV-1 regions induces CTL escape mutations that impair virus fitness and replication³⁵; this paves way for exploration of global vaccine approaches targeting highly conserved epitopes.^{16,36} Outstanding hurdles still exist, for example, while the STEP trial incorporated highly conserved regions in Gag, Pol, and Nef, it induced responses that were biased toward the less conserved epitopes³⁷ suggesting that the development of several regional vaccines may be more attainable. Consequently, strategies to improve immunological coverage of regionally circulating strains are concurrently under exploration.^{11,12}

Despite such setbacks, T cell HIV-1 vaccine development is crucial given the protective role of T cells remarkably demonstrated in infected individuals that efficiently control

viral loads.³⁸ This elite control has been attributed to enrichment with protective HLA class I alleles³⁹ and induction of robust HIV Gag T cell responses.⁴⁰ Further support is demonstrated by the coinciding of acute infection peak T cell responses with temporally reduction in viremia,⁴¹ impacting of early immune pressure on viral set point,⁴² the association between polyfunctional CD8⁺ T cells and slow disease progression,⁴³ and the promising data demonstrated in nonhuman primates.⁴⁴ Though the RV144 trial failed to induce CD8⁺ T cells and suggests an antibody correlate, robust CD4 T cell responses were elicited,³⁴ and these are critical for providing help for a durable effective antibody response. However, despite this body of evidence, immune correlates of protection remain unclear given that polyfunctional T cells have not always conferred protection in vaccinees.⁴⁵ Studies to elucidate valuable correlates of immune protection possibly through systems biology approaches are needed. Monitoring other aspects of the induced T cell responses such as differentiation status, migration patterns, proliferative, and survival capacity as well better understanding of their interplay with transmission routes, host factors, and viral fitness are necessary.

Our study had some unavoidable limitations: first, we did not sequence the *nef* and therefore could not interpret the relationship between HIV Nef diversity and induction of virus-induced T cell recognition. Second, the T cell recognition we report here possibly reflected an experimental selection of conserved epitopes since it is established that use of autologous sequences detects up to 30% more responses compared to consensus sequences.⁴⁶ We did not use autologous peptides because their use would have been very costly and impractical, and could not be translated into population strategies for HIV vaccine development. Third, direct comparison of these reagents to consensus clades A, B, C, and D would have allowed for an improved evaluation of the usefulness of the group M peptide sets in screening for HIV-specific T cell responses in this population. Lastly, we used IFN- γ ELISpot to demonstrate T cell cross recognition of these peptide sets. While IFN- γ ELISpot offers a quick screening tool for the detection of activated T cells, IFN- γ responses failed to predict the nonprotective effect of the

FIG. 5. Nef-induced IFN- γ responses (**A**, **B**) and their relationship to Gag IFN- γ responses (**C**, **D**). Cumulative magnitudes (SFU/10⁶ PBMCs) (**A**) and frequency of T cell recognition (**B**) of consensus group M Nef peptides are illustrated ($n=50$). Individual Nef peptides recognized are shown; sequences of dominant peptides targeted are indicated. To reasonably compare magnitudes and breadths induced by Gag (129 peptides) and Nef (53 peptides), the data were adjusted and presented as means to adjust for differences in the number of peptides evaluated per protein. Adjusted magnitudes (**C**) and breadths (**D**) of IFN- γ responses induced by Gag and Nef are shown. Floating bars represent minima and maxima while the horizontal lines represent medians.

STEP trial⁴⁷ and in our study lacked any correlations with viral loads (data not shown). Future studies would need to monitor other parameters of the induced T cell responses likely to predict protection.

Taken together, these data demonstrate that despite the ever-increasing diversity of HIV-1, peptides based on consensus HIV-1 group M sequences can be used to detect high frequencies of HIV-specific IFN- γ responses in a population predominantly infected with HIV-1 clades A1, D, and their associated recombinants. These findings also highlight the limitations of the use of these reagents in that they are biased toward detecting highly conserved epitopes.

Acknowledgments

We thank all the study participants and the dedicated clinical and field staff at TASO Entebbe. We thank the Medical Research Council/Uganda Virus Research Institute (MRC/UVRI) Uganda Research Unit on AIDS for enabling access to the study participants of the MRC/UVRI Entebbe cohort. The peptides: HIV-1 Group M Consensus Gag Peptides Set (#11057) and HIV-1 Group M Consensus Nef Peptides Set (#11055) were obtained through the NIH AIDS Research and Reference reagent program, Division of AIDS, NIAID, NIH: HIV-1 Gag Peptides Complete Set and HIV-1 Group M Consensus Nef Peptides Set. The study was funded by the International Atomic Energy Agency, project code RAF6/029, through a grant to the WHO/African AIDS Vaccine programme, with cofunding from the Medical Research Council (MRC UK). This work was also supported in part by a grant from the U.S. public health service to the Computational Biology Core of the University of Washington Center for AIDS research (AI 27757).

This manuscript has not been published in its current form or a substantially similar form. Part of this work was presented as an abstract at the AIDS Vaccine Conference, Paris, 19–22 October 2009. The abstract from this presentation was published as Serwanga J *et al.*, Persistence of robust cross-reactive group M consensus T cell responses in a chronic HIV-1 clade A1 and D-infected Ugandan population. *Retrovirology* 2009;6(Suppl 3):232 (22 October 2009).

Author Disclosure Statement

No competing financial interests exist.

References

- Lynch RM, Shen T, Gnanakaran S, and Derdeyn CA: Appreciating HIV type 1 diversity: Subtype differences in Env. *AIDS Res Hum Retroviruses* 2009;25(3):237–248.
- McCutchan FE: Global epidemiology of HIV. *J Med Virol* 2006;78(Suppl 1):S7–S12.
- Taylor BS, Sobieszczek ME, McCutchan FE, and Hammer SM: The challenge of HIV-1 subtype diversity. *N Engl J Med* 2008;358(April 10):1590–1602.
- Neogi U, Sood V, Banerjee S, *et al.*: Global HIV-1 molecular epidemiology with special reference to genetic analysis of HIV-1 subtypes circulating in North India: Functional and pathogenic implications of genetic variation. *Indian J Exp Biol* 2009;47(6):424–431.
- Hemelaar J, Gouws E, Ghys PD, and Osmanov S: Global trends in molecular epidemiology of HIV-1 during 2000–2007. *AIDS* 2011;25(5):679–689.
- Brander C, Frahm N, and Walker BD: The challenges of host and viral diversity in HIV vaccine design. *Curr Opin Immunol* 2006;18(4):430–437.
- Fischer W, Liao HX, Haynes BF, Letvin NL, and Korber B: Coping with viral diversity in HIV vaccine design: A response to Nickle *et al.* *PLoS Comput Biol* 2008;4(1):e15.
- Gao F, Weaver EA, Lu Z, *et al.*: Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. *J Virol* 2005;79(2):1154–1163.
- Nickle DC, Rolland M, Jensen MA, *et al.*: Coping with viral diversity in HIV vaccine design. *PLoS Comput Biol* 2007;3(4):e75.

10. Weaver EA, Lu Z, Camacho ZT, *et al.*: Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen. *J Virol* 2006;80(14):6745–6756.
11. Barouch DH, O'Brien KL, Simmons NL, *et al.*: Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. *Nat Med* 2010;16(3):319–323.
12. Santra S, Liao HX, Zhang R, *et al.*: Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. *Nat Med* 2010;16(3):324–328.
13. Rolland M, Jensen MA, Nickle DC, *et al.*: Reconstruction and function of ancestral center-of-tree human immunodeficiency virus type 1 proteins. *J Virol* 2007;81(16):8507–8514.
14. Gao F, Korber BT, Weaver E, *et al.*: Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity. *Expert Rev Vaccines* 2004;3(4 Suppl):S161–168.
15. Kothe DL, Li Y, Decker JM, *et al.*: Ancestral and consensus envelope immunogens for HIV-1 subtype C. *Virology* 2006;352(2):438–449.
16. Rolland M, Nickle DC, and Mullins JI: HIV-1 group M conserved elements vaccine. *PLoS Pathog* 2007;3(11):e157.
17. Serwanga J, Shafer LA, Pimego E, *et al.*: Host HLA B* allele-associated multi-clade Gag T-cell recognition correlates with slow HIV-1 disease progression in antiretroviral therapy-naïve Ugandans. *PLoS One* 2009;4(1):e4188.
18. Ngandu NG, Bredell H, Gray CM, Williamson C, and Seoighe C: CTL response to HIV type 1 subtype C is poorly predicted by known epitope motifs. *AIDS Res Hum Retroviruses* 2007;23(8):1033–1041.
19. Deng W, Nickle DC, Learn GH, Maust B, and Mullins JI: ViroBLAST: A stand-alone BLAST web server for flexible queries of multiple databases and user's datasets. *Bioinformatics* 2007;23(17):2334–2336.
20. de Oliveira T, Deforche K, Cassol S, *et al.*: An automated genotyping system for analysis of HIV-1 and other microbial sequences. *Bioinformatics* 2005;21(19):3797–3800.
21. Lole KS, Bollinger RC, Paranjape RS, *et al.*: Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of inter-subtype recombination. *J Virol* 1999;73(1):152–160.
22. Edgar RC: MUSCLE: Multiple sequence alignment with high accuracy and high throughput. *Nucleic Acids Res* 2004;32(5):1792–1797.
23. UNAIDS report on the Global epidemic, 2010.
24. Kiwanuka N, Laeyendecker O, Quinn TC, *et al.*: HIV-1 subtypes and differences in heterosexual HIV transmission among HIV-discordant couples in Rakai, Uganda. *AIDS* 2009;23(18):2479–2484.
25. Kiwanuka N, Laeyendecker O, Robb M, *et al.*: Effect of human immunodeficiency virus type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. *J Infect Dis* 2008;197(5):707–713.
26. McKnight A and Aasa-Chapman MM: Clade specific neutralising vaccines for HIV: An appropriate target? *Curr HIV Res* 2007;5(6):554–560.
27. Gao F, Liao HX, Hahn BH, *et al.*: Centralized HIV-1 envelope immunogens and neutralizing antibodies. *Curr HIV Res* 2007;5(6):572–577.
28. Frahm N, Nickle DC, Linde CH, *et al.*: Increased detection of HIV-specific T cell responses by combination of central sequences with comparable immunogenicity. *AIDS* 2008;22(4):447–456.
29. Bansal A, Gough E, Ritter D, *et al.*: Group M-based HIV-1 Gag peptides are frequently targeted by T cells in chronically infected US and Zambian patients. *AIDS* 2006;20(3):353–360.
30. Rutebemberwa A, Currier JR, Jagodzinski L, *et al.*: HIV-1 MN Env 15-mer peptides better detect HIV-1 specific CD8 T cell responses compared with consensus subtypes B and M group 15-mer peptides. *AIDS* 2005;19(11):1165–1172.
31. Yang OO: Candidate vaccine sequences to represent intra- and inter-clade HIV-1 variation. *PLoS One* 2009;4(10):e7388.
32. Barouch DH: Challenges in the development of an HIV-1 vaccine. *Nature* 2008;455(7213):613–619.
33. Johnston MI: An HIV vaccine-evolving concepts. *N Engl J Med* 2007;356(20):2073–2081.
34. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, *et al.*: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. *N Engl J Med* 2009;361(23):2209–2220.
35. Wang YE, Li B, Carlson JM, *et al.*: Protective HLA class I alleles that restrict acute-phase CD8+ T-cell responses are associated with viral escape mutations located in highly conserved regions of human immunodeficiency virus type 1. *J Virol* 2009;83(4):1845–1855.
36. Letourneau S, Im EJ, Mashishi T, *et al.*: Design and pre-clinical evaluation of a universal HIV-1 vaccine. *PLoS One* 2007;2(10):e984.
37. Li F, Finnefrock AC, Dubey SA, *et al.*: Mapping HIV-1 vaccine induced T-cell responses: Bias towards less-conserved regions and potential impact on vaccine efficacy in the Step Study. *PLoS One* 2011;6(6):e20479.
38. Baker BM, Block BL, Rothchild AC, and Walker BD: Elite control of HIV infection: Implications for vaccine design. *Expert Opin Biol Ther* 2009;9(1):55–69.
39. Emu B, Sinclair E, Hatano H, *et al.*: HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. *J Virol* 2008;82(11):5398–5407.
40. Miura T, Brockman MA, Schneidewind A, *et al.*: HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition. *J Virol* 2009;83(6):2743–2755.
41. Koup RA and Ho DD: Shutting down HIV. *Nature* 1994;370(6489):416.
42. Brockman MA, Brumme ZL, Brumme CJ, *et al.*: Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection. *J Virol* 2010;84(22):11937–11949.
43. Betts MR, Nason MC, West SM, *et al.*: HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. *Blood* 2006;107(12):4781–4789.
44. Hansen SG, Vieville C, Whizin N, *et al.*: Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. *Nat Med* 2009;15(3):293–299.
45. Betts MR, Exley B, Price DA, *et al.*: Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. *Proc Natl Acad Sci USA* 2005;102(12):4512–4517.
46. Altfeld M, Addo MM, Shankarappa R, *et al.*: Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences. *J Virol* 2003;77(13):7330–7340.

47. Buchbinder SP, Mehrotra DV, Duerr A, *et al.*: Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. *Lancet* 2008;372(9653):1881–1893.
48. Gilbert PB, Rossini AJ, Shankarappa R. Two sample tests for comparing intra-individual genetic sequence diversity between populations. *Biometrics* 2005;61(1):106–117.

Address correspondence to:
Jennifer Serwanga
MRC/UVRI Uganda Research Unit on AIDS
51-59 Nakiwogo Road
Entebbe
Uganda
E-mail: jennifer.serwanga@mrcuganda.org